cagrilintide semaglutide blend Cagrilintide–semaglutide (CagriSema) versus or in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study CAGRILINTIDE/SEMAGLUTIDE PEPTIDE (5MG/5MG) 10MG – Sema/Cag Blend - 10mg Vial

Participants were assigned to RT + PRO, RT only, or PRO only, receiving biweekly sessions for 24 weeks with controlled energy (30 kcal/kg/day) and protein intake (1.2 g/kg/day)

Patients who may particularly benefit from GLP-1 receptor agonists include those with type 2 diabetes and established cardiovascular disease, obesity, or chronic kidney disease (where SGLT2 inhibitors are not suitable or as additional therapy)

Apple cider vinegar focuses more on the "input" and "regulation" sidesupporting healthy blood sugar levels and digestion

Lynch, Jamisen A

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes